Effect of renal impairment on pharmacodynamics and pharmacokinetics of RO4998452: A multiple-center, open-label, parallel group study following single oral dosing of RO4998452 to Type 2 Diabetes patients with varying degrees of renal impairment.

Trial Profile

Effect of renal impairment on pharmacodynamics and pharmacokinetics of RO4998452: A multiple-center, open-label, parallel group study following single oral dosing of RO4998452 to Type 2 Diabetes patients with varying degrees of renal impairment.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2016

At a glance

  • Drugs Tofogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 15 Sep 2010 Status changed from active, no longer recruiting to completed as reported by Roche.
    • 25 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by Roche record.
    • 18 Feb 2010 Planned number of patients changed from 32 to 36 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top